Activation of the myeloid checkpoint inhibitor LILRB3 (ILT5) elicits profound immununomodulation
Purpose:To investigate the potential immunomodulatory function of a new panel of LILRB3-specific monoclonal antibody Overall design: Human peripheral blood monocytes were isolated from freshly prepared PBMCs taken from healthy donors. ). Cells were incubated in CTL medium supplemented with 100 U/ml Penicillin-Streptomycin, 2 mM Glutamine and HEPES buffer and treated with 10 µg/ml of an isotype control or an agonistic LILRB3 mAb (clone A1; hIgG1). 18 hours later, cells were lysed in RLT lysis buffer and total RNA extracted using the RNeasy micro kit for RNAseq.